Management of children with infantile hemangioma treated by systemic propranolol
Authors:
J. Mališ 1; A. Mišove 1; S. Zimová 1; K. Bláhová 2; V. Stará 2; N. Krejčová 2; M. Kynčl 3; M. Dvořáková 3; B. Prosová 3; M. Šimsová 4; R. Katra 5; A. Sukop 6
Authors‘ workplace:
Klinika dětské hematologie a onkologie 2. LF UK a FN Motol, Praha
1; Pediatrická klinika 2. LF UK a FN Motol, Praha
2; Klinika zobrazovacích metod 2. LF UK a FN Motol, Praha
3; Klinika dětské chirurgie 2. LF UK a FN Motol, Praha
4; Klinika ušní, nosní a krční 2. LF UK a FN Motol, Praha
5; Klinika plastické chirurgie 3. LF UK a FN Královské Vinohrady, Praha
6
Published in:
Čes-slov Pediat 2020; 75 (5): 285-291.
Category:
Review
Overview
Infantile hemangioma (IH) occurs in 5 to 10% of children under one year of age. This benign vascular tumor is characterized by three phases of growth – proliferation, plateau and involution. Modern non-selective β-blocker systemic therapy (propranolol) offers children an effective, safe and non-invasive solution. Starting the therapy in the proliferative phase is crucial for effectiveness.
Keywords:
infantile hemangioma – propranolol
Sources
1. Kilcline C. Infantile hemangiomas: How common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25 (2): 168–173.
2. Léauté-Labrèze C. Infantile haemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities. J Eur Acad Dermatol Venereol 2011; 25 (11): 1245–1253.
3. Baselga E. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatol 2016; 152 (11): 1239–1243.
4. Léauté-Labrèze C. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372 (8): 735–746.
5. Mališ J, Faberová R, Bučková H, et al. Současné terapeutické možnosti u infantilních hemangiomů. Čes-slov Dermatol 2017; 92 (2): 103–108. ISSN: 0009-0514.
6. Léauté-Labrèze C, Baselga Torres E, et al. The infantile hemangioma referral score: A validated tool for physicians. Pediatrics 2020 Apr; 145 (4): e20191628. doi: 10.1542/peds.2019-1628.
7. Léauté-Labrèze C. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358 (24): 2649–2651.
8. Vredenborg AD. Multiple cutaneous infantile haemangiomas and the risk of internal haemangioma. Br J Dermatol 2013; 169 (1): 188–191.
9. Chang L, Lv D, Yu Z, et al. Infantile hemangioma: factors causing recurrence after propranolol treatment. Pediatr Res 2018; 83: 175–182.
10. Bagazgoitia L, Hernandez-Martin A, Torrelo A. Recurrence of infantile hemangiomas treated with propranolol. Pediatr Dermatol 2011; 28: 658–662.
11. Mališ J, Stará V, Bláhová K, et al. Infantilní hemangiomy. Současné léčebné postupy. Čes-slov Pediat 2017; 72 (4): 245–254. ISSN: 0069-2328; 1805-4501
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2020 Issue 5
Most read in this issue
- Prof. MUDr. Jiří ZEMAN, DrSc. – jubileum
- COVID-19 pandemy from the perspective of regional children´s clinic
- Anemia in children with inflammatory bowel diseases
- Abdominal pain caused by retrocaval ureter